Market Intelligence, Clinical Progress, and High-Purity Reagents for Ferroptosis & Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALOX15/15-LOX drug discovery across multiple modalities.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALOX15 Recombinant Protein (WT & Mutant) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. HEK293 or E.coli expression available. |
View ALOX15 Products |
| Enzyme Inhibitor Screening | ALOX15 Activity Assay Kit Fluorescence-based lipoxygenase detection. Includes 15(S)-HETE standard. |
View ALOX15 Products |
| Gene Delivery | ALOX15 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Suitable for overexpression studies. |
View ALOX15 Products |
| Benchmark Ab | Anti-ALOX15 Benchmark Control Recombinant positive control for assay baselines. |
View ALOX15 Products |
| Validator | ALOX15 siRNA Set For knockdown verification and specificity controls. |
View ALOX15 Products |
| Related Target: GPX4 | Key regulator of ferroptosis and lipid peroxidation defense. | View GPX4 Products |
| Related Target: ALOX5 | Arachidonic acid cascade enzyme. Critical for selectivity screening (off-target liability). | View ALOX5 Products |
| Related Target: ALOX12 | Related lipoxygenase isoform. Important for subfamily specificity assays. | View ALOX12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (Subfamily counter screening vs. 5-LOX, 12-LOX) | Homolog Panel Proteins strictly verified by Mass Spec (>95% purity). Human/Mouse/Rat orthologs available. |
| Enzymatic Activity Standardization | Sequence Verified WT protein with documented specific activity (nmol/min/mg). Include positive control inhibitor (PD146176 analog). |
| Mutant Validation (Drug Resistance) | Custom Point Mutants available (e.g., catalytic site variants). Sequence Verified, endotoxin controlled. |
| Structural Stability of Intracellular Enzymes | High-purity recombinant proteins optimized for structural integrity and Theoretical MW precision. |
| Cellular Context Assays | High-titer Lentivirus particles for stable ALOX15-overexpressing cell lines. Suitable for compound penetration studies. |
| Lack of Controls / False Positives | Sequence Verified Benchmark Antibodies and Validated siRNA included for reliable assay baselines and strict specificity checks. |
Live ALOX15/15-LOX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Inhibitor Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ALOX15/15-LOX therapeutics is intensifying. First-generation pan-lipoxygenase inhibitors faced off-target toxicity issues, driving the next wave of R&D toward highly selective small molecule inhibitors targeting ferroptosis, lipid peroxidation, and inflammatory diseases. Key indications include neurodegenerative diseases (Alzheimer's, Parkinson's), ischemia-reperfusion injury, severe asthma, COPD, atherosclerosis, and immuno-oncology. As first-generation therapies approach advanced preclinical phases, the market remains in early-stage with no approved drugs, offering significant opportunities for first-in-class therapies. The development of targeted protein degradation (PROTAC) and oligonucleotide modalities is also emerging for indications where selective inhibition is challenging.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic/Biotech Consortiums; Bayer, Incyte, J&J | Neurodegeneration, Stroke, Asthma, Atherosclerosis | Selectivity Assay (Need Homolog Panel Proteins: ALOX5, ALOX12, ALOX15) |
| Isoform-Selective Inhibitor | AstraZeneca, Novartis | COPD, Psoriasis | Selectivity Panel (Need ALOX5, ALOX12, ALOX15 homolog proteins for cross-screening) |
| Dual LOX/FLAP Inhibitor | GSK, Boehringer Ingelheim | Cardiovascular | Mechanism Validation (Need siRNA controls for target engagement confirmation) |
| Targeted Protein Degradation (PROTAC) | Early-stage Innovators | Severe Asthma / COPD | Degradation Validation (Need High-purity Intracellular Protein & Benchmark Abs) |
| RNAi / Antisense | Oligonucleotide Biotechs | Atherosclerosis | Target Knockdown Verification (Need Validated siRNA Controls) |